Overweight and Obesity as Risk Factors for Chemotherapy-Induced Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia

Skrypnyk, І. М.; Маслова, Ганна Сергіївна; Lymanets, T.

doi:10.26724/2079-8334-2022-2-80-146-150

Cited by 2 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…До того ж, у пацієнтів ІІІ групи виявлено прямий кореляційний зв'язок між активністю АЛТ і АСТ (r=0,95; р=0,01). Таким чином, можна думати, що прогресія В-ХЛЛ із розвитком тромбоцитопенії асоціюється із порушенням білковосинтетичної функції печінки [8]. Розвиток уражень печінки цитолітичного типу характеризується комбінованим зростанням активності амінотрансфераз.…”

Section: результати дослідженняunclassified

“…За результатами нашого дослідження виявлено асоціацію прогресії онкогематологічного захворювання із ураженнями печінки цитолітичного типу, який характеризувався прямим кореляційним зв'язком високої сили між рівнем лейкоцитів та активністю трансаміназ і вмістом білірубіну у сироватці крові хворих на В-ХЛЛ. Отримані нами результати співпадають із даним інших дослідників, які засвідчують, що пухлинна інфільтрація тканин печінки може характеризуватись розвитком синдрому цитолізу із зростанням активності АСТ у сироватці крові пацієнтів [8][9][10]12].…”

Section: обговоренняunclassified

See 1 more Smart Citation

Identifying Risk Factors for Treatment Failure in B-Cell Chronic Lymphocytic Leukemia Patients Receiving Bendamustine±rituximab Therapy

Drabovska,

Maslova

2024

Act. Probl. of the Modern Med.

View full text Add to dashboard Cite

Introduction. The initial assessment of prognosis is of particular importance in determining the management of patients with B-cell chronic lymphocytic leukemia and the choice of specific therapy. The aim is to analyze the risk factors for failure to achieve a complete response to the bendamustine±rituximab treatment regimen in patients with B-cell chronic lymphocytic leukemia. Materials and methods. Twenty-two patients undergoing treatment for B-cell chronic lymphocytic leukemia (B-CLL) progression were included in the study. Response to treatment was assessed on the 56th day, categorized as complete, partial, or no response. Patients were divided into three groups based on their response: group I (n=6) included patients who showed a complete response after receiving bendamustine±rituximab; group II (n=11) included patients who achieved a partial response; and group III (n=5) consisted of patients with no response. Risk factors for chemotherapy resistance, as well as general and biochemical blood counts, were evaluated and subjected to statistical analysis. Results: Stage III (C) and IV (C) according to the Rai, Binet classification were recorded in 33.2% of patients with a complete response to chemotherapy, in 36.4% of patients with a partial response to chemotherapy, and in 60% of patients with no response to specific treatment. A decrease in hemoglobin level below 100 g/L was recorded only in patients with a partial response and no response, namely in 4 (36%) patients of group II and 1 (20%) patient of group III. On day 56, in patients of group II who received a partial response, there was a direct correlation between the level of leukocytes in the hemogram and the activity of aspartate aminotransferase (r=0.71; p=0.01) and the content of total bilirubin (r=0.63; p=0.03) in the biochemical blood test. After 2 courses of chemotherapy in patients of group III, a direct correlation of high strength between the level of leukocytes in the hemogram and the activity of aspartate aminotransferase (r=0.93; p=0.02) and alanine aminotransferase (r=0.93; p=0.02) in the biochemical blood test was found. The bendamustine±rituximab chemotherapy regimen has a high safety profile.

show abstract

Section: результати дослідженняunclassified

Section: обговоренняunclassified

Identifying Risk Factors for Treatment Failure in B-Cell Chronic Lymphocytic Leukemia Patients Receiving Bendamustine±rituximab Therapy

Drabovska,

Maslova

2024

Act. Probl. of the Modern Med.

View full text Add to dashboard Cite

show abstract

Diagnostic Significance of Various Radiological Methods in the Detection of Pathological Changes in the Liver Against of Background of Diabetes Mellitus

Najafova

2023

WOMAB

View full text Add to dashboard Cite

Overweight and Obesity as Risk Factors for Chemotherapy-Induced Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia

Cited by 2 publications

References 15 publications

Identifying Risk Factors for Treatment Failure in B-Cell Chronic Lymphocytic Leukemia Patients Receiving Bendamustine±rituximab Therapy

Identifying Risk Factors for Treatment Failure in B-Cell Chronic Lymphocytic Leukemia Patients Receiving Bendamustine±rituximab Therapy

Diagnostic Significance of Various Radiological Methods in the Detection of Pathological Changes in the Liver Against of Background of Diabetes Mellitus

Contact Info

Product

Resources

About